Therapies targeting the neuro-vascular-immune triad show promise for treating rosacea but lack large-scale randomized controlled trials.
This review summarizes rosacea treatments targeting the neuro-vascular-immune triad, including γ-aminobutyric acid derivatives, antidepressants, anti-calcitonin gene-related peptide agents, physical neuromodulation, botulinum toxin type A, and β-blockers. The authors note that while these therapies can specifically regulate different stages of the pathway, their evidence lacks large-scale randomized controlled trials and clarity regarding optimal dosing regimens and treatment durations.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Therapies targeting the neuro-vascular-immune triad show promise for treating rosacea but lack large-scale randomized controlled trials. The current body of evidence comprises 1 study. EvidenceHub rates the overall confidence at 32/100 (low).
The Claim
Therapies targeting the neuro-vascular-immune triad show promise for treating rosacea but lack large-scale randomized controlled trials.
This conclusion is most relevant to: Patients with rosacea.
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Therapeutic progress in rosacea: targeting the neuro-vascular-immune triad. (Frontiers in immunology, 2026) —
How It Works
The proposed biological pathway:
- ▸Abnormal activation of the neuro-vascular-immune triad is a crucial pathological mechanism of rosacea
- ▸Dysregulation within the central nervous system may exacerbate disease progression by modulating peripheral nerve activity and neuroendocrine homeostasis
- ▸Therapies target different stages of this pathway
- ▸Result: Potential reduction in rosacea symptoms
Who Might Benefit
Evidence fit by population:
- ▸Patients with rosacea
Recommended Dose
N/A
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Lack of large-scale randomized controlled trials
- ▸Unclear optimal dosing regimens and treatment durations
Frequently Asked Questions
What is the neuro-vascular-immune triad in rosacea?▼
It is a proposed pathological mechanism involving abnormal interactions between the nervous system, blood vessels, and immune system that contribute to rosacea symptoms.
Which therapies are reviewed for targeting this triad?▼
The review covers γ-aminobutyric acid derivatives, antidepressants, anti-calcitonin gene-related peptide agents, physical neuromodulation (transcutaneous auricular vagus nerve and repetitive transcranial magnetic stimulations), botulinum toxin type A, and β-blockers.
What are the main limitations of current evidence for these therapies?▼
The evidence lacks large-scale randomized controlled trials and clarity regarding optimal dosing regimens and treatment durations.
Does this paper focus on sleep disturbances in rosacea?▼
The abstract mentions sleep disturbances as a complication of severe rosacea, but the primary focus is on treatments targeting the neuro-vascular-immune triad, not sleep specifically.
References
- 1.Yang X, Yang W, Chen N, Li D, Xu Y. “Therapeutic progress in rosacea: targeting the neuro-vascular-immune triad..” Frontiers in immunology, 2026. PMID: 42440475 DOI: 10.3389/fimmu.2026.1876564